Citizens raised the firm's price target on Precigen to $9 from $8 and keeps an Outperform rating on the shares. Precigen reported Q4 updates highlighting strong early commercial traction for PAPZIMEOS, guiding to more than $18M in Q1 sales and reaffirming funding through cash flow break-even, the analyst tells investors in a research note. With broad patient engagement, solid reimbursement access, and advocacy support, PAPZIMEOS appears well positioned to lead the recurrent respiratory papillomatosis market as the first and only approved therapy, the firm says.
